Neurol. praxi 2017; 18(Suppl F): 9-12 | DOI: 10.36290/neu.2017.123

Treatment of multiple sclerosis with oral cladribine: results of clinical trials

MUDr. Ivana Kovářová
Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN, Praha

Cladribine tablets has been registered recently for treatment of relapsing multiple sclerosis. The article presents results of thepivotal clinical trial CLARITY and its extension – efficacy of cladribine tablets on clinical and radiological outcomes, and safetyand tolerability data.

Keywords: multiple sclerosis, cladribine

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kovářová I. Treatment of multiple sclerosis with oral cladribine: results of clinical trials. Neurol. praxi. 2017;18(Suppl.F - Aktuální pohled na...):9-12. doi: 10.36290/neu.2017.123.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Soelberg S?rensen P, Vermersch P, Hamlett A, Viglietta V, Greenberg S. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol 2013; 260: 1136-11346. Go to original source... Go to PubMed...
    2. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Soelberg S?rensen P, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg S. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011; 17: 578-593. Go to original source... Go to PubMed...
    3. Cook S, Comi G, Rieckmann P, Rammohan K, Soelberg S?rensen P, Vermersch P, Martin E, Dangond F, Giovannoni G. Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY study. Poster 3.326 at AAN, 15-21 April 2016. Go to original source...
    4. Cook S, Leist T, Comi G, Montalban X, Sylvester E, Hicking C, Dangond F. Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development programme. Poster P644 at ECTRIMS, 12-15 September 2016.
    5. De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal Jan 2017; 1-5 [Epub ahead of print] doi.org/10.1177/1352458517690269. Go to original source... Go to PubMed...
    6. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S?rensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg S. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. NEJM 2010; 362: 416-426. Go to original source... Go to PubMed...
    7. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Soelberg S?rensen P, Vermersch P, Hamlett A, Viglietta V, Greenberg S. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011; 10: 329-337. Go to original source... Go to PubMed...
    8. Giovannoni G, Comi G, Cook S, Rieckmann P, Rammohan K, Soelberg S?rensen P, Vermersch P, Martin E, Dangond F. Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY study. Poster P3.028 at AAN, 15-21 April 2016. Go to original source...
    9. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(Suppl. 3): S3-S7. Go to original source... Go to PubMed...
    10. Montalban X, Cohen B, Leist T, Moses H, Hicking C, Dangond F. Safety and tolerability of cladribine tablets added to IFN-beta therapy in patients with active relapsing multiple sclerosis: final results from the ONWARD study (amended protocol). Poster 1209 at European Academy of Neurology, 2nd Annual Congress, Copenhagen, May 28-31 2016.
    11. Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2015; 2(6): e158. Go to original source... Go to PubMed...
    12. Souhrn údajů o přípravku přípravku Mavenclad.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.